Race- and sex-specific disease trajectory in individuals with rare variants in

seven cerebrovascular small vessel disease genes: a genotype-first population

study

Jiang Li[1], Vida Abedi[1,2], Durgesh Chaudhary[3], Regeneron Genetics Center[7], Oded

Goren[4], David J. Carey[1], Karen E. Wain[5], Ramin Zand[3,6]

[1]Department of Molecular and Functional Genomics, Weis Center for Research, Geisinger Health System, Danville,

Danville, PA 17822, USA

[2]Department of Public Health Sciences, College of Medicine, The Pennsylvania State University, Hershey, PA 17033,

USA.

[3]Neuroscience Institute, Geisinger Health System, Danville, PA 17822, USA.

[4]Department of Neurosurgery, Geisinger Health System, Danville, PA 17822, USA

[5]Autism & Developmental Medicine Institute, Geisinger Health System, Danville, PA 17822, USA.

[7]Regeneron Genetics Center, LLC, Tarrytown, NY 10591, USA

[6]Department of Neurology, College of Medicine, The Pennsylvania State University, Hershey, PA 17033, USA

Corresponding Author:

Ramin Zand MD, MPH, FAHA.

Email: ramin.zand@gmail.com

Jiang Li Ph.D

Email: jli@geisinger.edu

Conflict of Interest Disclosures: J Li, D Chaudhary, DJ Carey, O Goren, KE Wain, R

Zand, and V Abedi report no disclosures relevant to the manuscript.

Word count:

Figures: 5

Tables: 1

Supplementary Figures and Tables: 9 and 1

Supplementary Material for Method.

Keywords: monogenic disease, RV, IS, cerebral small vessel disease, age of onset, relative risk, percent relative effect, burden test, survival analysis, Cox proportional hazards regression, hazard ratio, electronic health records.

Glossary

ACMG = American College of Medical Genetics and Genomics; **AFR** = African

ancestry; **CI** = confidence interval; **CoxPH** = Cox proportional-hazards model; **CSVD** =

cerebral small vessel disease; **EHR** = Electronic Health Record; **eQTL** = expression

quantitative trait loci; **EUR** = European ancestry**; GO** = Gene Ontology; **GWAS** =

genome-wide association study; **Hazards ratio** = HR; **HGMD** = Human Gene Mutation

Database; **HWE** = Hardy-Weinberg Equilibrium; **ICD** = International Classification of

Disease; **IS** = IS; **LAS** = large-artery strokes; **LD** = linkage disequilibrium; **MAF** = minor

allele frequency; **ML** = machine learning; **OR** = odds ratio; **PSEA** = PheCode Set

Enrichment Analysis; **PTV =** protein truncation variants; **RD** = risk difference**; RR** =

relative risk; **RV** = RV; **PCA** = Principal Component Analysis; **PRE** = percent relative

effect; **PRS** = polygenic risk score; **SNP** = single nucleotide polymorphism; **TIA** =

transient ischemic attack; **VEP** = Ensembl Variant Effect Predictor; **VUS** = a variant of

uncertain significance.

Key Points:

Question Is there an increased risk for a lifetime or early onset of cardiovascular diseases and others within or beyond the circulatory system observed in rare variant carriers of seven well-characterized monogenic cerebral small vessel disease (CSVD) risk genes (*COL4A1, COL4A2, NOTCH3, HTRA1, TREX1, CTC1,* and *GLA*)?

Findings In this retrospective longitudinal study of 175K individuals, which were temporally split into discovery (2738/5490) and replication cohorts (1695/3410) for carriers/matched noncarriers, *NOTCH3* ($HR_{earlyonset} = 2.175$ for White), *TREX1* ($HR_{earlyonset} = 4.006$ for White), and COL4A1/2 ($HR_{earlyonset} = 2.163$ for Black) were associated with ischemic stroke, particularly in female participants. *HTRA1* also showed a similar trend. Circulatory diseases were overrepresented in discovery and replication cohorts with an early onset of cardiovascular phenotypes irrespective of race.

Meaning Carriers for monogenic CSVD risk genes demonstrated the increased risk for the lifetime or early onset of cardiovascular disease and diseases within or beyond the circulatory system, some of which are race- and sex- dependent.

Abstract:

Background: This study is aimed to explore the risk for a lifetime or early onset of cardiovascular diseases and diseases within or beyond the circulatory system observed in rare variant(RV) carriers of seven well-characterized monogenic cerebral small vessel disease (CSVD) risk genes (*COL4A1, COL4A2, NOTCH3, HTRA1, TREX1, CTC1,* and *GLA*) using a genotype-first approach within a hospital system population-based biobank cohort.

Method: This was a retrospective longitudinal study. MyCode participants with sequenced exomes were temporally split into discovery (n=92,445) and replication (n=81,130) cohorts. A workflow was created to prioritize potentially pathogenic variants by integrating three variant annotation pipelines. After propensity score matching, the number of participants in both discovery and replication cohorts was 2738/5490 and 1695/3410 for carriers/noncarriers, respectively.

Result: Most of the RVs identified were in a heterozygous form and disproportionately present in participants with African ancestry. Carriers showed an increased risk for early signs and symptoms of cerebrovascular disease. Cox regression model showed *NOTCH3* (European), *TREX1* (European), and COL4A1/2 (African) were associated with ischemic stroke. Circulatory diseases were overrepresented in discovery and replication cohorts with an early-onset of cardiovascular phenotypes irrespective of race. Sex- and race-dependent effect for cerebrovascular disease risk was clearly detectable, particularly for *NOTCH3(*$HR_{earlyonset}$ = 2.175[1.391-3.403], p = 0.001*),* and

TREX1(HR$_{earlyonset}$ = 4.006[1.797-8.931], p = 0.001). *COL4A1/2*(HR$_{earlyonset}$ = 2.163[0.87-

5.38], p = 0.097). *HTRA1* (European) also showed a similar trend of association.

Conclusion: Carriers for monogenic CSVD risk genes demonstrated the increased risk

for the lifetime or early onset of cerebrovascular disease and diseases within or beyond

the circulatory system, some of which in a race- and sex-dependent manner. Our

findings support the concept of developing a gene panel of CSVD for population

screening of patients with early-onset circulatory diseases.

1. Introduction

Exome sequencing has made it possible to identify rare variants(RVs) in known genes causing monogenic stroke at both familial and population levels[1-4]. Previous attempts have been made to compile a comprehensive gene panel based on earlier linkage studies of monogenic stroke with Mendelian inheritance[5,6]. Whether used for familial[5] or population[7,8] screening, this technology, which combines exome capture and targeted sequencing, has demonstrated its potential to identify risk for monogenic stroke with early[5] or late onset[7,8].

Incomplete penetrance, variable expressivity, and pleiotropy lead to the phenotypic diversity[9] and become potential obstacles to promoting exome sequencing in diagnosis of monogenic cerebral small vessel disease (CSVD). These obstacles include: 1) Limited knowledge of **lifetime incidence** of disease among individuals with RVs identified from risk genes; 2) **Subtype dependency** of risk genes leading to varied effect size[10]; 3) **Variable expressivity** of phenotypes in patients with rare heterozygous variants for monogenic diseases[11,12]; 4) **Incomplete penetrance** of pathogenic variants which could be modified by age for late-onset diseases[9], even for autosomal dominant disorders[11,13-15]; 5) **Race- and sex-dependency** in monogenetic diseases with complex disease profiles[6,9,16]; 6) **Predisposition symptoms**[17] (e.g. transient ischemic attack (TIA)[18], hypercoagulability[19], atrial fibrillation[20]), and patterns of comorbidities that have not been explored in individuals with RVs – leading to opportunities for personalized prevention strategy; 7) Development of a variety of small vessel-related phenotypes beyond the brain[21] and circulatory system[22-24] at the early stage in carriers (**Pleiotropy**). Finally, stroke is an ultimate expression of a systemic failure in arteriolar function[25].

Geisinger's comprehensive Electronic Health Record (EHR) intersected with MyCode

exome sequencing for genomic screening make it possible to identify potentially

pathogenic variants in biobank-leveled population and associated disease profile and

trajectory[1,11,26,27].

The purpose of this study is to identify rare, potentially pathogenic variants of seven

well-characterized monogenic CSVD risk genes (*COL4A1, COL4A2, NOTCH3, HTRA1,*

TREX1, CTC1, and *GLA*) using a genotype-first approach within a healthcare system

population-based biobank cohort. The goal is to explore the clinical manifestations

observed in variant carriers and assess the risk for the lifetime or early onset of CSVD

and other diseases within or beyond the circulatory system.

2. Method:

2.1 Participating cohorts

This was a retrospective longitudinal study with a two-step design. The Geisinger

patient population with comprehensive EHR was intersected with the MyCode initiative

for exome sequencing of blood samples, which was performed through the DiscovEHR

collaboration between Geisinger and the Regeneron Genetics Center (Tarrytown, New

York) [1,26,28,29]. The Geisinger Institutional Review Board approved this study to meet

"Non-human subject research" using de-identified information. All research was

performed in accordance with relevant guidelines/regulations. Informed consent was

obtained from all participants and/or their legal guardian(s). The participants and

analysis pipeline are illustrated in **Figure 1**.

The MyCode participants, a predominantly adult population with European ancestry,

were temporally split into discovery (n=92,445) and replication (n=81,130) based on the

time of dataset availability.

2.2 Genetic data

Probes (xGen Exome Research Panel v1.0.) from Integrated DNA Technologies (IDT)

were used for the exome capture. Sequencing was performed by 75bp paired-end

reads on Illumina HiSeq2500. Coverage depth was sufficient to provide more than 90%

coverage for 99% of samples. Samples with low-quality sequence data or showing

discordance of sex from self-reported sex or genotypes from array-based data were

removed.

Alignments and variant calling were based on the human GRCh38 reference genome.

Variant calls were produced by the WeCall variant caller (Genomics PLC, Version

1.1.2). A project variant-call file (pVCF) was compiled using the GLnexus[30] joint

genotyping tool (version 1.1.3-4). Sample level variant calls with site read depth (DP)

<15, Phred-scaled genotype quality score (GQ) < 40, and alternate allele balance <15%

(or fewer than 5 alternate reads) were removed. The call rate was 99.97%. Participants

with the missing genotyping call (<0.001%) were considered null for the rare allele.

2.3 Prioritization of potentially damaging rare variants

RVs from seven risk genes for monogenic CSVD were identified from pVCFs by three

variant annotation pipelines [31]. They were *COL4A1* (OMIM:120130), *COL4A2*

(OMIM:120090), *NOTCH3* (OMIM:600276), *HTRA1* (OMIM:602194), *GLA* (OMIM:

300644), *CTC1* (OMIM:613129), and *TREX1* (OMIM:606609) as shown in

Supplementary Figure 1. Both *COL4A1* and *COL4A2* are located on 13q34. They are

structurally expressed and typically function together. Thus, we treated them as one in

this study. Variants were initially filtered by minor allele frequency (MAF) because the

rate of pathogenic variation was lower due to selection constraints. Only variants with

MAF < 0.001 from gnomAD and MAF < 0.01 from the MyCode population were

considered as rare and subjected to the following variants annotation process. The MAF

cutoffs were empirically determined based on the characteristics of each study

population.

VEP annotation was conducted on 12/29/2019 using Ensemble web interface

(https://useast.ensembl.org/info/docs/tools/vep/index.html), and the result in

Supplementary Table 1 was updated on 01/24/2022.

Pipeline 1(P1): RVs with functional impact predicted to be 'moderate' by VEP annotation

were subsequently filtered by HGMD (professional 2018.2 released) annotation[32]. Only

variants predicted to be 'disease modifying' (DM) entered the final variant assessment

process.

Pipeline 2(P2): RVs with functional impact predicted to be 'high' by VEP annotation

were retained[33]. All of them are predicted loss-of-function (LoF) variants with enriched

protein truncation variants (PTVs).

Pipeline 3(P3): RVs in ClinVar annotated as 'pathogenic' (P) or 'likely pathogenic' (LP),

without conflicting assertions (as of 12/29/2019 database and updated on 01/24/2022

database) were selected[34]. ACMG interpretation criteria were applied[34] and no VUS

variants were included.

For variants with minor allele count (MAC) < 3 in the entire MyCode population,

participant-level quality control (QC) data (GT, DP, AD, GQ, SBPV) from pVCF file or

individual CRAM file for mapping/alignment were accessed by Integrative Genomics

Viewer (https://software.broadinstitute.org/software/igv/home) to determine the final

genotyping call.

Based on the above RV selection criteria(P1-3), we identified a total of 188 RVs in the

discovery cohort. We further filtered out some RVs (n = 121) due to 1) conflict reports of

significance based on ACMG criteria[34]; 2) more stringent sequencing QC score for rare

frameshift variants; 3) clear evidence of benign variants reported by ACMG but

identified by HGMD as 'disease modifying'; 4) prior knowledge based on a literature

search (*in vitro* functional studies as well as pedigree studies). Our preliminary study

using *NOTCH3* as an example showed that adding this filtering process would help to

enrich the pathogenic variants with higher penetrance (data not shown).

The prioritized 67 RVs, including their genotype counts as well as functional

consequence (HGVSp) are illustrated in **Supplementary Figure 1** using UCSC

Genome Browser (GRCh38/hg38). Additional tracks from ClinVar, HGMD, OMIM, and

Pfam Domains (GENCODE database) were mapped to those variants.

2.4 Phenotype data

Geisinger billing codes for diagnostics at any encounter setting were mapped to the

International Classification of Disease (ICD)-related ICD9 and ICD10 codes.

Demographic information was extracted from the structured EHR. ICD-9 and ICD-10

diagnostic codes were combined and mapped to 1,866 hierarchical PheCodes[35], each

representing a specific disease phenotype. Rollup PheCodes without clinical definition

of disease were removed from the subsequent analyses. All the PheCodes were

grouped into 18 disease categories, such as the Circulatory system, the Genitourinary

system, and more, as shown in a longitudinal layout (Figure 1). Study participants were

labeled with a PheCode if they had one or more PheCode-specific ICD codes. "Case"

was defined as all study participants with the PheCode of interest, and "control" was

defined as all study participants without the PheCode of interest during their lifetime or

within a predefined observation window for early-onset (e.g., ≤65yrs). To avoid an

uneven sampling of the disease trajectory, which might lead to temporal bias in the

longitudinal study, we also tested the age cutoff at 60 years or 55 years. Sex, as a

biological variable, was included during the mapping process so that sex-specific

PheCodes would not be mislabeled.

2.5 Comparability of variant carriers and non-carriers

Propensity score matching (PSM) to control confounding was applied to obtain the

'counterfactual' control group. Race, sex, and index age, which were denoted as the

last active (last encounter) date, were identified as potential confounding factors. Other

unmeasured confounding factors were assumed to be correlated with these factors and

their confounding effects would be largely reduced after matching. They were selected

as covariates in a Logistic Regression model to create propensity scores (R 'MatchIt'

package). We chose "nearest neighbor matching without replacement" to create a more

balanced carrier:noncarrier ratio at 1:2, as shown in **Supplementary Figure 2**; this step

ensured that the standardized mean differences (SMD) for the matched variables were

within ± 0.1. The number of participants in both cohorts was 2738/5490 and 1695/3410,

respectively. For noncardiovascular-related common diseases, Risk Differences (RD)

were < 0.1 for lifetime and early onset (≤65yr) in both cohorts, suggesting no selection

bias between the carrier and noncarrier groups[36].

2.6 Outcome measures

Major outcome variables in this study included age of onset, relative risk (RR) and

percent relative effect (PRE).[37]

Risk Ratio (Relative Risk, RR) is defined as, $Risk\ Ratio = \frac{Cl_e}{Cl_u}$, where (Cl_e) = cumulative

incidence among the exposed subjects, and (Cl_u) is the cumulative incidence among

unexposed subjects. The relative risk (or risk ratio, RR) is an intuitive way to compare

the risks for the two groups.

$RR - 1$ is defined as the percent change in the exposed group (carriers). We consider

the unexposed group (noncarriers) as having 100% of the risk, and the phenotype

expression of the exposed group, expressivity, is relative to that. PRE, or $RR - 1$, is

alternatively interpreted as a normalized RD with a positive or negative value. The PRE

for each phenotype after exposure is similar to the percentage change in gene

expression after exposure. This parameter will be used for PheCode set enrichment

analysis, a counterpart of gene set enrichment analysis, to calculate the enrichment

score.

$$Percent\ Relative\ Effect = \frac{Risk\ Difference}{Cl_u} = \frac{Cl_e - Cl_u}{Cl_u} = RR - 1$$

A circo plot was created based on the top 50 PheCodes ranked by PRE and clustered

by the processes. This representation shows the extracerebral disease manifestations

and overrepresentation while the rainbow links represent the association between

PheCodes in carriers.

2.7 Statistics

Categorical data are reported as number (percentage); continuous data are presented

as mean (SD), as indicated. Statistical analyses were performed using R, version 3.6.

All mapped PheCodes were divided into common (with a better mapping performance[38])

or rare diseases by the prevalence (<1%) of the disease estimated from noncarriers.

Fisher's exact test was conducted to determine the frequency difference between

PheCodes in carriers and noncarriers. Due to imbalanced case-control ratios for rare

diseases which may lead to inflated statistical significance, only the associations

between common diseases were reported. There were 756 common PheCodes

mapped for 4433 participants, in which 695 or 580 phenotypes had case-control ratios

greater than 1:100 (regarded as common diseases) for both cohorts, respectively.

Survival analyses and Kaplan-Meier estimator for cumulative incidence probability were

conducted (R 'survival' and 'survminer' packages). Participants were considered at risk

of diseases at lifetime (for up to 85 years of follow-up) or early onset (age of onset > 65

years was considered as null and were censored at the last active date or the date of

data extraction (06/12/2021). Multivariate Cox proportional hazards model, adjusted for

confounding variables (sex, index age, and 5 main principal components from PCA)

was also performed and the hazard ratio for phenotypes of interest at lifetime as well as

early-onset (≤65 years) was calculated. The proportional hazards assumption was

verified using Schoenfield residuals. For all analyses, $p < 0.05$ was considered

statistically significant. For all post-hoc pairwise tests, p-values were present as raw.

2.8 Subgroup analyses

Subgroup analyses were conducted by stratifying the participants based on race (EUR

or AFR), sex, and gene. The early onset was defined as patients with the first diagnosis

before 65 years old. We also tested 60 and 55 years as cutoffs to determine if the trend

of association or expressivity (PRE) remained valid. We evaluated the effect size

(Hazard Ratio, HR) of RVs associated with PheCodes or PheCode sets in a multivariate

CoxPH model in all samples as well as subgroups stratified by sex, race, and gene. All

subgroup analyses were considered exploratory and p-values were present as raw.

2.9 PheCode Set Enrichment Analysis (PSEA)

PheCode Set Enrichment Analysis was conducted to determine which PheCode set

from a disease category (e.g., circulatory system) was significantly enriched against a

randomly selected PheCode set (same number) from that category. In this study, we

only focused on common diseases, the prevalence of which in the MyCode population ≥

1%. Using pre-ranked differential gene expression data to conduct gene-set enrichment

analysis (GSEA) inspired us to develop the PSEA. The general idea of the PSEA

method is to test whether the distribution of PheCodes in the PheCode-set differed from

a uniform distribution. To achieve this goal, we used the established ranking metric

strategy used in GSEA – namely, signed statistic (e.g., disease-level PRE) was selected

as a substitute to the statistics of differential gene expression used in GSEA.

fgsea[39] is an R-package for fast pre-ranked gene set enrichment analysis.

(https://github.com/ctlab/fgsea). Here we adopt the idea and procedure of GSEA. The

preranked PheCode-level statistics S (PRE) for the PheCode U = {1, 2, …, N} and a list

of query PheCode sets, P, resulting in Max(ES) per disease category. This analysis

aims to determine which of the PheCode sets from P has a non-random behavior.

Fgsea used a gene set enrichment score function $s_r(p)$ originally defined by

Subramanian et al[40]. The more positive is the value of $s_r(p)$ the more enriched the

gene set is in the positively-regulated genes (with $S_i > 0$). Accordingly, negative $s_r(p)$

corresponds to enrichment in the negatively regulated genes. Value of $s_r(p)$ can be

calculated as follows. Let $k = |p|, NS = \sum_{i \in p} |S_i|$. Let also ES be an array specified by

the following formula[39]:

$$ES_i = \begin{cases} 0 & if\ i = 0 \\ ES_{i-1} + \dfrac{1}{NS}|S_i| & if\ 1 \leq i \leq N\ and\ i \in p, \\ ES_{i-1} - \dfrac{1}{N-k} & if\ 1 \leq i \leq N\ and\ i \notin p. \end{cases}$$

298 The value of $s_r(p)$ correspond to the largest by the absolute value entry of ES[39]:

$$s_r(p) = ES_{i^*},\ where\ i^* = argmax|ES_i|$$

299 Following Subramanian et al. [40] for a pathway, p, Korotkevich et al. define GSEA p-

300 value as[39]:

$$P_{value}(p) = \begin{cases} \dfrac{P_k(s_r(q) \geq s_r(p))}{P_k(s_r(q) \geq 0)} & if\ s_r(p) > 0 \\ \dfrac{P_k(s_r(q) \leq s_r(p))}{P_k(s_r(q) \leq 0)} & if\ s_r(p) < 0 \end{cases}$$

Where q is a random gene set of size k.

NES = enrichment score normalized to mean enrichment of random samples of

the same size of tested PheCode-set. P-value estimation is based on an adaptive multi-

level split Monte-Carlo scheme, which allows for estimating a lower p-value (< 10^{-5}). To

speed up the process, fgsea divides the entire ranked PheCodes into n blocks and tries

all the thresholds to get the minimum p-value. P-value adjustment for multiple testing of

a number of PheCode sets was conducted using the Benjamin-Hochberg procedure.

The codes are available at [GitHub - TheDecodeLab/Trajectory-of-Monogenic-Diseases:

Development of a platform to observe and analyses the trajectory of monogenic

diseases](#).

Result:

Participants Demographics

The entire dataset was temporally split based on the availability of the sequencing data. Demographic and clinical features for the discovery and replication cohorts are listed in **Table 1a**. We identified a total of 4,446 RV carriers of at least one of the seven candidate genes out of 173,575 MyCode participants. Initial EHR data extraction was completed on 12/29/2019 for a pilot study of the discovery cohort; the second EHR data extraction was completed on 12/06/2021 for both discovery and replication cohorts. After removing carriers without longitudinal EHR data (at least two encounters separated by at least one month), we end up with 4433 (2738/1695) carriers. Five-fold noncarriers, 22,250 (13,725/8525) were randomly sampled from noncarriers in each cohort. The prevalence of any diseases in the MyCode population was estimated by these randomly selected noncarriers. After PSM at a 1:2 ratio, there was no significant difference in sex, race (EUR or AFR), or the index age between carriers and noncarriers. The replication cohort was, on average, five years younger than the discovery cohort. This difference may lead to some findings from the discovery cohort not being replicated in the younger cohort, particularly for late-onset diseases.

Distribution of RVs identified by three pipelines

A total of 24 participants had RVs from any two genes. Around 20.18% (569/2738 and 329/1695) or 40.61% (1244/2738 and 563/1695) of participants had at least second/third-degree relatedness based on PiHAT score of 0.20 or 0.10, respectively. Most participants (94.45%/86.96%) are self-claimed White and confirmed with EUR ancestry by Principal Component Analysis (PCA). A smaller portion of participants

(4.77%/11.79%) are self-claimed Black and confirmed with AFR ancestry by PCA.

Participants from other ethnical groups were < 2% and were not included for further

analysis.

Missense (38 distinct variants), stop gain (12), NMD (nonsense-mediated decay),

transcript variant (8), and splice donor (5)/acceptor (7) variants were the top categories

of VEP annotated consequence (**Supplementary Table 1**), suggesting these potential

pathogenic variants may have an impact on protein function at the various levels.

In **Table 1a**, most participants with RVs were female in both cohorts. RVs were mainly

identified in *COL4A1/2* and *NOTCH3* genes (**Table 1b**).

According to PSM plots (**Supplementary Figure 2**), RVs were observed

disproportionately more in participants with AFR ancestry (for the unadjusted sample,

SMD deviated to the right side for AFR, whereas SMD deviated to the left side for EUR)

in both cohorts. The majority of identified RVs were in heterozygous form. Compared to

the replication cohort, the discovery cohort had more participants (EUR: 60.70% vs.

38.54%; AFR: 95.42% vs. 89.05%) with *COL4A1/2* variants but fewer participants

(EUR:22.37% vs. 34.57%; AFR: 0% vs. 2.49%) with *NOTCH3* variants. The

distributions of RVs from the other four genes across the two cohorts were comparable

(p > 0.05 by Fisher's exact test) (**Table 1b**).

Three variant annotation pipelines were applied to capture potentially damaging RVs.

RVs derived from P2 were enriched with putative loss of function variants affecting RNA

splicing (splice donor and acceptor variants) or translation (start lost, stop gained, and

stop lost). However, the replication cohort had fewer participants identified from pipeline

2 with these consequences (**Supplementary Figure 3**). It was noted that many of the

RVs prioritized by P2 were singleton or doubleton with acceptable QC data. Using

PheCodes related to the circulatory system as examples, we explored the performance

of the three pipelines. These PheCodes showed a stronger percent relative effect (PRE)

in either discovery or replication cohorts (**Supplementary Figure 3**). P1 showed the

largest PRE (green bar) in most of the PheCodes than other pipelines or the intersect

pipeline (red bar), suggesting that P1 augmented the performance of the P3 (purple

bar), the ClinVar annotation. A similar observation was reported by others[41]. In some

PheCodes, P2 (blue bar) showed the largest $PREs$, particularly in the discovery cohort

but less obvious in the replication cohort, perhaps due to fewer carriers (44% versus

10%) exclusively identified by P2. Since three pipelines show their capability of

identifying positive cases ($PRE \geq 0$) for some but not all tested PheCodes at varying

degrees, carriers identified from all pipelines were combined for the following study.

Top PheCodes with the largest PRE were overrepresented in early-onset patients

The circo plot (**Supplementary Figure 4**) demonstrated the top 50 PheCodes ranked

by PRE, grouped by the process. Unlike AFR participants with overrepresented

phenotypes in the circulatory system, EUR participants did not show any disease

categories represented excessively in the top 50 PheCodes with increased lifetime risk.

Only in early-onset patients, diseases from the circulatory system were exclusively

overrepresented in the top 50 PheCodes in both EUR and AFR participants (**Figure 2**).

Primary cardiomyopathy was the only shared PheCode in the circulatory system in

early-onset EUR between discovery and replication cohorts, whereas several

PheCodes related to cerebral vascular diseases were top-ranked in the lifetime and

early-onset AFR cohorts.

It was noted that all PheCode links between and within categories were specific to

carriers in both AFR cohorts since no links were identified in noncarriers. However,

some links identified in both EUR cohorts were shared by carriers and noncarriers. For

example, the links between cardiac and circulatory congenital anomalies and heart

valve disease were identified in both carriers (Figure 3), particularly for *COL4A1/2*

(Supplementary Figure 5) and noncarriers.

For individual genes (e.g., *COL4A1/2* and *NOTCH3*) in the early-onset study, PheCodes

from the circulatory system were overrepresented in the top 50 common diseases in

both discovery and replication cohorts (**Supplementary Figure 5**). However, this

observation was valid only in *TREX1 and CTC1* in the replication cohort. The increased

risk for cardiac and circulatory congenital anomalies[22,23 42] was identified in the EUR

discovery cohort (**Figure 2**), particularly for *COL4A1/2* **(Supplementary Figure 5)**.

Some connections between CSVD genes with phenotypes beyond cardiovascular

systems were captured. These secondary findings included: 1) *GLA* and thyroid

diseases; It was previously suggested that a physiological concentration of thyroid

hormone directly facilitates matrix Gla protein gene expression in smooth muscle cells

via thyroid hormone nuclear receptors, leading to prevention of vascular calcification [24];

2) *COL4A1/2 and HTRA1* with renal findings (hematuria)[23], and *COL4A1/2* with

abnormal function of bladder[43]; 3) *HTRA1* and musculoskeletal disease[44].

Notably, some common cerebrovascular disease-related phenotypes (such as TIA,

primary cardiomyopathy, atrial fibrillation, and hypercoagulability) were top ranked with

an increased relative risk in at least one cohort. The links between TIA and

cardiomyopathy and cerebral ischemia and carditis were captured in the discovery

cohort of EUR carriers but not in noncarriers. The link between occlusion of cerebral

arteries and chronic venous insufficiency was identified only in AFR carriers but not in

noncarriers in the replication cohort.

Race-, and Sex- dependent association

The entire gene-specific survival analysis is illustrated in **Figure 3**. In the discovery

cohort, *COL4A1/2* or *NOTCH3* variants showed the (trend of) association with IS in AFR

or EUR participants, respectively. In the replication cohort, *COL4A1/2 or TREX1*

variants showed a similar (trend of) association with IS in AFR or EUR participants,

respectively. When combined both AFR cohorts (**Figure 4C**), *COL4A1/2* was

significantly associated with IS ($HR_{lifetime}$=2.032(1.065-3.875), p=0.031). It was noted

that *HTRA1* carriers had an increased cumulated incidence of IS in the late-onset

participants from both discovery and replication cohorts (the green curve spikes after

65yr in **Figure 3A-3B**).

Sex-dependent association was demonstrated in **Figure 4**. In the discovery cohort, the

effect sizes were larger in female participants ($HR_{earlyonset}$=1.499[1.046-2.148], p=0.027

for *COL4A1/2* and 2.175[1.39-3.401], p < 0.001 for *NOTCH3* in EUR; 2.343[0.713-

7.701], p=0.161 for *COL4A1* in AFR). In the replication cohort, female patients with

early-onset IS showed larger effect sizes ($HR_{earlyonset}$=2.445[0.584-10.232], p=0.221 for

COL4A1/2 in AFR; 4.006[1.797-8.931], p<0.001 for *TREX1* in EUR). However, these

findings for *NOTCH3* or *TREX1* were not observed in the replication or discovery

cohort, respectively. AFR participants had no RVs identified for *NOTCH3*. This sex-

dependent effect also appeared in *HTRA1* carriers after combining samples from both

discovery and replication cohorts with a trend of increased effect size in female carriers

($HR_{lifetime}$=1.758[0.654-4.722], p=0.263) but not in male carriers $HR_{lifetime}$=0.98[0.377-

2.72], p=0.98).

COL4A1/2 variants were associated with hypercoagulability in EUR participants in the

discovery cohort ($HR_{lifetime}$=1.49[1.065-2.084], p=0.020). The trend of association was

observed in the replication cohort ($HR_{lifetime}$=1.626[0.856-3.085], p=0.137)

(**Supplementary Figure 7A**). Effect sizes were larger for *COL4A1/2*

($HR_{earlyonset}$=1.963[1.285-2.998], p = 0.002) in EUR female participants of

hypercoagulability, but not for *NOTCH3* ($HR_{earlyonset}$=1.194[0.57-2.501], p = 0.638) in the

discovery cohort. However, this significant association was only observed in the

replication male cohort ($HR_{earlyonset}$= 5.113[1.649-15.854], p = 0.005). The association

between *COL4A1/2* variants and hypercoagulability was also identified in male AFR

participants ($HR_{earlyonset}$=5.113[1.649-15.854], p = 0.005). No connection between

hypercoagulability and cerebrovascular disease was observed by Fisher's exact test in

all genes (**Figure 2**) or *COL4A1/2*-only (**Supplementary Figure 5**) in the discovery

cohort. The connection between hypercoagulability and heart valve disorders was only

observed in carriers (**Figure 2 and Supplementary Figure 5**) but not in noncarriers

(data not shown) in the EUR discovery cohort. The association between HTRA1 and

hypercoagulability was identified in the discovery EUR cohort and validated in the

replication EUR cohort (**Supplementary Figure 7**).

CTC1 had a significant association with primary cardiomyopathies[425.1] with a

stronger signal in the replication EUR cohort ($HR_{earlyonset}$=8.463[2.608-27.466],

p=0.0006; $HR_{lifetime}$=4.601[1.433-14.674], p=0.010) than in the discovery EUR cohort

($HR_{earlyonset}$=4.568[1.118-18.663], p=0.034; $HR_{lifetime}$=2.779[0.883-8.752], p=0.081)

(**Supplementary Figure 7B**). *TREX1* only demonstrated a significant association with

primary cardiomyopathies in the replication EUR cohort ($HR_{earlyonset}$=3.146[1.403-7.054],

p = 0.005; $HR_{lifetime}$=2.386[1.184-4.810], p=0.015).

PheCode-set Enrichment Analysis in early-onset patients

The top enriched disease category was circulatory system in both discovery (N = 18,

NES = 2.95, p_{adj} = 2.8×10^{-10} for EUR; N = 20, NES = 2.43, p_{adj} = 2.7×10^{-9} for AFR) and

replication cohorts (N = 20, NES = 2.22, p_{adj} = 2.8×10^{-7} for EUR; N = 20, NES=2.36, p_{adj}

= 8.5×10^{-8} for AFR (**Figure 5 and Supplementary Figure 8**). Validation across cohorts

or across racial groups was also performed using the PheCode set derived from

circulatory system as an example (**Figure 5D**). Neither the replication EUR cohort (NES

= 1.10, p_{adj} = 0.97) nor the discovery AFR cohort (NES = 1.61, p_{adj} = 0.12) validated the

enriched PheCode set from the discovery EUR cohort. The enriched PheCode set from

the discovery AFR cohort was marginally replicated in the replication AFR cohort (NES

= 1.72, p_{adj} = 0.083), but was not replicated in the discovery EUR cohort (NES = 0.77,

p_{adj} = 0.96). The enriched PheCode set from the replication EUR or AFR cohort was

mutually replicated each other (NES = 2.02, p_{adj} = 7.1×10^{-4} or NES = 1.89, p_{adj} = 1.6×10^{-3}

^{3} in the replication AFR or EUR cohort, respectively).

Discussion:

There is an unmet need to evaluate the lifetime risk and the variability in age of onset for cerebrovascular disease by leveraging large-scale biobank datasets linked to comprehensive EHRs, and to identify potentially actionable genomic variants that may contribute to monogenic IS. As the management of individuals with monogenic causes for their diseases could be different from patients with polygenic or non-genetic etiology, this diagnostic attribution in common disease could alter the care options[17].

In this study, using a workflow to prioritize potentially pathogenic variants by an integration of three variant annotation pipelines, we showed that 1) Most of the RVs identified were in a heterozygous form and disproportionately present in AFR participants; 2) Inclusion of participants with ultra-RVs, which predicted to have a 'high' functional impact and have not been observed in ClinVar and/or HGMD, may augment the disease profiling; 3) *NOTCH3* , *TREX1, and COL4A1/2* were associated with IS in a race- and sex-dependent manner (more frequent among women); 4) Circulatory diseases were overrepresented in discovery and replication cohorts with early-onset of cardiovascular phenotypes irrespective of race; 5) Carriers of the seven genes showed increased risk for early signs and symptoms of cardiovascular disease such as, TIA, cardiomyopathy, atrial fibrillation, and hypercoagulability; and 6) Major findings from the PheCode enrichment analysis were replicated among AFR participants or the replication cohort(p_{adj} < 0.1 for PheCode sets derived from circulatory system from both cohorts).

Our phenome-wide analyses on RVs carriers with mostly heterozygous genotypes confirmed the pleiotropic and non-additive effects which were reported on homozygous

carriers of PTVs, so-called "human knockouts" in a UK Biobank study[45]. We also

confirmed that the *HTRA1* carriers had an increased risk for IS, particularly in the late-

onset EUR participants. There is a conflict report between *in vitro* functional study[2,46]

and *in silicon*-based prediction[47] about whether or not the *HTRA1*-p.Gln151Lys variant

is deleterious. Most *HTRA1* carriers with EUR ancestry (103/120) were heterozygous

for p.Gln151Lys, located at N-terminal domain with IGFBP and Kazal homology[46].

According to the Kaplan-Meier analyses (**Supplementary Figure 9),** p.Gln151Lys

carries alone also had an increased risk for late-onset IS, suggesting its damaging

effect. We argued that it is still valid to develop a knockout model to determine the

functional effect of *HTRA1* IGFBP/Kazal domain within and beyond the cardiovascular

system despite its *in vitro* null effect on protease activity[46].

Our finding indicated that female carriers had a significantly increased risk for IS during

menopause and the elderly stage than male carriers(Figure 4), suggesting there may

have some cause for the incomplete penetrance and variable expressivity in male

compared to females[9], and it is important to recognize the sex differences in precision

medicine for IS[48].

Some of the findings identified in EUR participants were not replicated, likely due to

their small effect sizes in the EUR, overrepresentation of participants of younger age,

and some RVs being over- or under-represented in the replication cohort[10]. Given the

extensive connection among PheCodes observed in the discovery EUR but not in the

replication EUR (**Figure 2**), the disease trajectories for carriers in the discovery EUR

could be more complicated than those observed in replication cohorts. This complexity

may determine if the PheCode sets derived from one cohort show significant

enrichment in the other cohort.

Various factors may account for the possibility of replication in an independent cohort.

The validity of the results is determined by empirical variant curation (ACMG Clinvar

annotation[49]) or machine learning algorithms (VEP annotation[50] + additional

approach[32]), which are used to prioritize functional variants. Using a comparative

approach, we identified some discrepancies due to the variant annotation pipelines

(**Supplementary Figure 3**). This discrepancy could result from the varied functional

impact of each variant, their allele frequency and conservation, and their interaction with

environmental factors (lifestyle, social determinants, and more) at the patient level.

Observations and conclusions made from monogenic diseases:

1. RVs with large effects:

The main driver for some variants with extremely low frequency is due to natural

selection; however, the 'reversal rare' theory for protective alleles also exists[45]. Thus,

the success of this study depends on the number of genuinely causal variants, the

number of neutral variants or protective variants diluting signals, and whether the

direction of effect is consistent within the gene. As we mentioned earlier, the additional

filtering process for RVs would help enrich true deleterious RVs with higher penetrance.

Type II error may occur due to including fewer RVs for some candidate genes.

2. The omnigenic model – Core and peripheral genes:

Most genes affect disease risk through highly connected gene regulatory/expression

networks[51]. While RVs from the core genes demonstrate a larger effect size, peripheral

genes exert their effects through interaction with core genes. For an omnigenic disease

model, adding more 'peripheral' genes into the 'core' genes could lead to the diluted

impacts with an increase in the false-positive results[10,51]. "The omnigenic model predicts

that virtually any variant with regulatory effects in a given tissue is likely to have (weak)

effects on all diseases that are modulated through that tissue"[51]. Instead of testing RVs

individually, grouping variants with a similar function or belonging to genes within a

similar functional network could boost the power of the association study. Pathway

enrichment analysis of *COL4A1, NOTCH3,* and *HTRA1* coexpression networks in

approximately 20 transcriptomic datasets from cardiovascular diseases showed

'extracellular matrix organization' as the top GO Biological Process terms

(https://seek.princeton.edu/seek/). *COL4A1, NOTCH3,* and *HTRA1* are also highly

correlated at the transcriptional level. In contrast, *CTC1* (T cell receptor signaling

pathway), *GLA* (cellular response to lipopolysaccharide), and *TREX1*(cellular response

to interferon) were mostly related to inflammation and immune response. Therefore, the

overall effect from the seven candidate genes mainly reflected the disease profile due to

the damage of the extracellular matrix or matrisome disfunction[52].

3. Pleiotropy and disease trajectory:

Horizontal and vertical pleiotropy of monogenic variants results in diverged disease

profile and trajectory. Extracerebral phenotypes are common in monogenic CSVD risk

genes. The large-scale population-based phenome-wide longitudinal study of health

outcomes could promote a better understanding of under-investigated disease trajectory

beyond the brain[21]. Deep Phenotyping and Phenotypes conversion (stacking,

orthogonal, deconvolution) enhance computing trajectories from wellness to disease for

genetically predisposed individuals[53]. We must be cautious when the PTVs are enriched

by the pipeline 2 (P2) selection; the latter may lead to patients with different disease

trajectories or more patients with certain early-onset diseases compared to damaging

missense variants enriched by P1 and P3 selections (**Supplementary Figure 3**). A

similar observation of the rare or ultra-rare PTVs versus damaging missense variants

across the phenotypic spectrum was also reported[54]. Genetic screening of patients with

an early-onset of circulatory diseases for RVs of CSVD risk genes would prioritize

individuals for continuous granular monitoring and promote personalized management.

Study strength and limitation:

This study had some strengths, such as leveraging rich longitudinal EHR, comparing

three variants-annotation pipelines, and conducting PheCodes enrichment and

sensitivity analyses to determine the sex- and age-dependent association. However, the

study also has some limitations. First, the small sample size for participants reporting

AFR ancestry and other ethnicities may prevent us from adequately estimating the

effect size from those populations. Second, a potential underdiagnosis for carriers with

mild phenotype is an inherent challenge of EHR-based observational study[55]. This

would lead to an underestimation of the prevalence of genetically predisposed traits as

the early sign or symptoms of advanced phenotypes (e.g., stroke or heart failure)[17].

Pathogenic variants resulting in mild phenotypes may survive natural selection during

reproductive age but increase the risk for mid- and late-onset diseases. Third, RVs

identified by the three pipelines were limited to missense, splicing, and stop gain/lost

sequence variants. Finally, the pleiotropic effect and varied effect sizes for each RV

complicated the overall disease profiles and trajectories assessment. The varied

expressivity of carriers could be due to an interplay between complex (polygenic) and

Mendelian (monogenic) genetics[14] for IS; the common disease is more complex than

the implied "core genes" model[56]. Polygenic Risk Scores (PRS) derived from common

variants could modify the outcome of patients with a monogenic disease[14,57,58]. How

PRS modify the outcome of patients with RVs of monogenic risk genes will be the future

focus.

Conclusion:

• Some common cardiovascular disease-related phenotypes (TIA, primary

cardiomyopathy, atrial fibrillation, and hypercoagulability) were identified at an

increased relative risk in RV carriers of seven CSVD risk genes.

• RVs from *COL4A1/2* or *NOTCH3* and *TREX1* were associated with IS in

participants with AFR or EUR ancestry, respectively. Effect sizes are

significantly larger in female participants. *HTRA1* carriers with EUR ancestry also

showed a similar trend of association.

• Diseases from the circulatory system were significantly enriched in carriers with

both EUR and AFR ancestry.

• Our findings support the concept of developing a gene panel of CSVD for

population screening of patients with early-onset circulatory diseases. Under this

clinical scenario, the diagnostic attribution through genetic testing is actionable.

Whether the inclusion of CSVD genes on population-based genomic

screening/ACMG secondary findings lists (which would be phenotype-agnostic)

remains debatable.

Reference:

Dewey, F. E. *et al.* Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. *Science* **354**, doi:10.1126/science.aaf6814 (2016).

Malik, R. *et al.* Whole-exome sequencing reveals a role of HTRA1 and EGFL8 in brain white matter hyperintensities. *Brain* **144**, 2670-2682, doi:10.1093/brain/awab253 (2021).

Mishra, A. *et al.* Association of variants in HTRA1 and NOTCH3 with MRI-defined extremes of cerebral small vessel disease in older subjects. *Brain* **142**, 1009-1023, doi:10.1093/brain/awz024 (2019).

Rutten, J. W. *et al.* The effect of NOTCH3 pathogenic variant position on CADASIL disease severity: NOTCH3 EGFr 1-6 pathogenic variant are associated with a more severe phenotype and lower survival compared with EGFr 7-34 pathogenic variant. *Genet Med* **21**, 676-682, doi:10.1038/s41436-018-0088-3 (2019).

Ilinca, A. *et al.* A stroke gene panel for whole-exome sequencing. *Eur J Hum Genet* **27**, 317-324, doi:10.1038/s41431-018-0274-4 (2019).

Grami, N. *et al.* Global Assessment of Mendelian Stroke Genetic Prevalence in 101 635 Individuals From 7 Ethnic Groups. *Stroke* **51**, 1290-1293, doi:10.1161/STROKEAHA.119.028840 (2020).

Hack, R. J. *et al.* Cysteine-Altering NOTCH3 Variants Are a Risk Factor for Stroke in the Elderly Population. *Stroke* **51**, 3562-3569, doi:10.1161/STROKEAHA.120.030343 (2020).

Rutten, J. W. *et al.* Broad phenotype of cysteine-altering NOTCH3 variants in UK Biobank: CADASIL to nonpenetrance. *Neurology* **95**, e1835-e1843, doi:10.1212/WNL.0000000000010525 (2020).

Kingdom, R. & Wright, C. F. Incomplete Penetrance and Variable Expressivity: From Clinical Studies to Population Cohorts. *Front Genet* **13**, 920390, doi:10.3389/fgene.2022.920390 (2022).

Nicolae, D. L. Association Tests for Rare Variants. *Annu Rev Genomics Hum Genet* **17**, 117-130, doi:10.1146/annurev-genom-083115-022609 (2016).

Oetjens, M. T., Kelly, M. A., Sturm, A. C., Martin, C. L. & Ledbetter, D. H. Quantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders. *Nat Commun* **10**, 4897, doi:10.1038/s41467-019-12869-0 (2019).

Goodrich, J. K. *et al.* Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes. *Nat Commun* **12**, 3505, doi:10.1038/s41467-021-23556-4 (2021).

Forrest, I. S. *et al.* Population-Based Penetrance of Deleterious Clinical Variants. *JAMA* **327**, 350-359, doi:10.1001/jama.2021.23686 (2022).

Vuckovic, D. *et al.* The Polygenic and Monogenic Basis of Blood Traits and Diseases. *Cell* **182**, 1214-1231 e1211, doi:10.1016/j.cell.2020.08.008 (2020).

Choi, S. H. *et al.* Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation. *JAMA* **320**, 2354-2364, doi:10.1001/jama.2018.18179 (2018).

Hall, M. A. *et al.* Detection of pleiotropy through a Phenome-wide association study (PheWAS) of epidemiologic data as part of the Environmental Architecture for Genes Linked to Environment (EAGLE) study. *PLoS Genet* **10**, e1004678, doi:10.1371/journal.pgen.1004678 (2014).

Murray, M. F., Khoury, M. J. & Abul-Husn, N. S. Addressing the routine failure to clinically identify monogenic cases of common disease. *Genome Med* **14**, 60, doi:10.1186/s13073-022-01062-6 (2022).

18 Shahjouei, S. *et al.* Risk of Subsequent Stroke Among Patients Receiving Outpatient vs Inpatient
Care for Transient Ischemic Attack: A Systematic Review and Meta-analysis. *JAMA Netw Open* **5**,
e2136644, doi:10.1001/jamanetworkopen.2021.36644 (2022).
19 Siegerink, B., Maino, A., Algra, A. & Rosendaal, F. R. Hypercoagulability and the risk of
myocardial infarction and ischemic stroke in young women. *J Thromb Haemost* **13**, 1568-1575,
doi:10.1111/jth.13045 (2015).
20 Diaz, J. *et al.* Adherence to anticoagulant guideline for atrial fibrillation: A large care gap among
stroke patients in a rural population. *J Neurol Sci* **424**, 117410, doi:10.1016/j.jns.2021.117410
(2021).
21 Rannikmae, K. *et al.* Beyond the Brain: Systematic Review of Extracerebral Phenotypes
Associated With Monogenic Cerebral Small Vessel Disease. *Stroke* **51**, 3007-3017,
doi:10.1161/STROKEAHA.120.029517 (2020).
22 Kuo, D. S., Labelle-Dumais, C. & Gould, D. B. COL4A1 and COL4A2 mutations and disease:
insights into pathogenic mechanisms and potential therapeutic targets. *Hum Mol Genet* **21**, R97-
110, doi:10.1093/hmg/dds346 (2012).
23 Meuwissen, M. E. *et al.* The expanding phenotype of COL4A1 and COL4A2 mutations: clinical
data on 13 newly identified families and a review of the literature. *Genet Med* **17**, 843-853,
doi:10.1038/gim.2014.210 (2015).
24 Sato, Y. *et al.* Thyroid hormone targets matrix Gla protein gene associated with vascular smooth
muscle calcification. *Circ Res* **97**, 550-557, doi:10.1161/01.RES.0000181431.04290.bd (2005).
25 Thompson, C. S. & Hakim, A. M. Living beyond our physiological means: small vessel disease of
the brain is an expression of a systemic failure in arteriolar function: a unifying hypothesis.
Stroke **40**, e322-330, doi:10.1161/STROKEAHA.108.542266 (2009).
26 Carey, D. J. *et al.* The Geisinger MyCode community health initiative: an electronic health
record-linked biobank for precision medicine research. *Genet Med* **18**, 906-913,
doi:10.1038/gim.2015.187 (2016).
27 Jurgens, S. J. *et al.* Analysis of rare genetic variation underlying cardiometabolic diseases and
traits among 200,000 individuals in the UK Biobank. *Nat Genet*, doi:10.1038/s41588-021-01011-
w (2022).
28 Abul-Husn, N. S. *et al.* Genetic identification of familial hypercholesterolemia within a single U.S.
health care system. *Science* **354**, doi:10.1126/science.aaf7000 (2016).
29 Li, J. *et al.* Polygenic Risk Scores Augment Stroke Subtyping. *Neurol Genet* **7**, e560,
doi:10.1212/NXG.0000000000000560 (2021).
30 Yun, T. *et al.* Accurate, scalable cohort variant calls using DeepVariant and GLnexus.
Bioinformatics, doi:10.1093/bioinformatics/btaa1081 (2021).
31 Kelly, M. A. *et al.* Leveraging population-based exome screening to impact clinical care: The
evolution of variant assessment in the Geisinger MyCode research project. *Am J Med Genet C*
Semin Med Genet **187**, 83-94, doi:10.1002/ajmg.c.31887 (2021).
32 Stenson, P. D. *et al.* The Human Gene Mutation Database: towards a comprehensive repository
of inherited mutation data for medical research, genetic diagnosis and next-generation
sequencing studies. *Hum Genet* **136**, 665-677, doi:10.1007/s00439-017-1779-6 (2017).
33 Li, Y. I. *et al.* RNA splicing is a primary link between genetic variation and disease. *Science* **352**,
600-604, doi:10.1126/science.aad9417 (2016).
34 Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint
consensus recommendation of the American College of Medical Genetics and Genomics and the
Association for Molecular Pathology. *Genet Med* **17**, 405-424, doi:10.1038/gim.2015.30 (2015).
35 Wu, P. *et al.* Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development and
Initial Evaluation. *JMIR Med Inform* **7**, e14325, doi:10.2196/14325 (2019).

36 Schuemie, M. J. *et al.* A plea to stop using the case-control design in retrospective database
studies. *Stat Med* **38**, 4199-4208, doi:10.1002/sim.8215 (2019).
37 Monaghan, T. F. *et al.* Foundational Statistical Principles in Medical Research: A Tutorial on Odds
Ratios, Relative Risk, Absolute Risk, and Number Needed to Treat. *Int J Environ Res Public Health*
18, doi:10.3390/ijerph18115669 (2021).
38 Wei, W. Q. *et al.* Evaluating phecodes, clinical classification software, and ICD-9-CM codes for
phenome-wide association studies in the electronic health record. *PLoS One* **12**, e0175508,
doi:10.1371/journal.pone.0175508 (2017).
39 Korotkevich, G. *et al.*, doi:10.1101/060012 (2021).
40 Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for
interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* **102**, 15545-15550,
doi:10.1073/pnas.0506580102 (2005).
41 Park, J. *et al.* Exome-wide evaluation of rare coding variants using electronic health records
identifies new gene-phenotype associations. *Nat Med* **27**, 66-72, doi:10.1038/s41591-020-1133-
8 (2021).
42 Steffensen, L. B. & Rasmussen, L. M. A role for collagen type IV in cardiovascular disease? *Am J
Physiol Heart Circ Physiol* **315**, H610-H625, doi:10.1152/ajpheart.00070.2018 (2018).
43 Rouaud, T. *et al.* Acute urinary retention due to a novel collagen COL4A1 mutation. *Neurology*
75, 747-749, doi:10.1212/WNL.0b013e3181eee440 (2010).
44 Tiaden, A. N. & Richards, P. J. The emerging roles of HTRA1 in musculoskeletal disease. *Am J
Pathol* **182**, 1482-1488, doi:10.1016/j.ajpath.2013.02.003 (2013).
45 DeBoever, C. *et al.* Medical relevance of protein-truncating variants across 337,205 individuals in
the UK Biobank study. *Nat Commun* **9**, 1612, doi:10.1038/s41467-018-03910-9 (2018).
46 Eigenbrot, C. *et al.* Structural and functional analysis of HtrA1 and its subdomains. *Structure* **20**,
1040-1050, doi:10.1016/j.str.2012.03.021 (2012).
47 Di Donato, I. *et al.* Heterozygous mutations of HTRA1 gene in patients with familial cerebral
small vessel disease. *CNS Neurosci Ther* **23**, 759-765, doi:10.1111/cns.12722 (2017).
48 Bushnell, C. *et al.* Sex differences in the evaluation and treatment of acute ischaemic stroke.
Lancet Neurol **17**, 641-650, doi:10.1016/S1474-4422(18)30201-1 (2018).
49 Amendola, L. M. *et al.* Performance of ACMG-AMP Variant-Interpretation Guidelines among
Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. *Am J Hum Genet*
98, 1067-1076, doi:10.1016/j.ajhg.2016.03.024 (2016).
50 McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **17**, 122,
doi:10.1186/s13059-016-0974-4 (2016).
51 Boyle, E. A., Li, Y. I. & Pritchard, J. K. An Expanded View of Complex Traits: From Polygenic to
Omnigenic. *Cell* **169**, 1177-1186, doi:10.1016/j.cell.2017.05.038 (2017).
52 Debette, S. & Markus, H. S. Stroke Genetics: Discovery, Insight Into Mechanisms, and Clinical
Perspectives. *Circ Res* **130**, 1095-1111, doi:10.1161/CIRCRESAHA.122.319950 (2022).
53 MacRae, C. A. & Califf, R. M. Reimagining What We Measure in Atherosclerosis-a "Phenotype
Stack". *Circ Res* **126**, 1146-1158, doi:10.1161/CIRCRESAHA.120.315941 (2020).
54 Ganna, A. *et al.* Quantifying the Impact of Rare and Ultra-rare Coding Variation across the
Phenotypic Spectrum. *Am J Hum Genet* **102**, 1204-1211, doi:10.1016/j.ajhg.2018.05.002 (2018).
55 Casey, J. A., Schwartz, B. S., Stewart, W. F. & Adler, N. E. Using Electronic Health Records for
Population Health Research: A Review of Methods and Applications. *Annu Rev Public Health* **37**,
61-81, doi:10.1146/annurev-publhealth-032315-021353 (2016).
56 Wray, N. R., Wijmenga, C., Sullivan, P. F., Yang, J. & Visscher, P. M. Common Disease Is More
Complex Than Implied by the Core Gene Omnigenic Model. *Cell* **173**, 1573-1580,
doi:10.1016/j.cell.2018.05.051 (2018).

57   Giudicessi, J. R. & Ackerman, M. J. Determinants of incomplete penetrance and variable
expressivity in heritable cardiac arrhythmia syndromes. *Transl Res* **161**, 1-14,
doi:10.1016/j.trsl.2012.08.005 (2013).
58   Li, J. *et al.* Predicting mortality among ischemic stroke patients using pathways-derived
polygenic risk scores. *Sci Rep* **12**, 12358, doi:10.1038/s41598-022-16510-x (2022).

Table 1. Patient characteristics of RVs carriers or noncarriers in both Discovery

and Replication cohorts.

The study cohort was split into Discovery and Replication datasets and further split according to having RVs or not. All continuous variables were reported as mean (standard deviation), and dichotomous variables were reported as absolute count (frequency). For disease phenotype, we reported the absolute count of patients having lifetime and early-onset of the corresponding PheCode from Geisinger EHR. For the lifetime observation, patients were followed up to 85 years; Patients with age of onset after 65yrs considered null for the early-onset cases. ANOVA or Fisher's exact test was selected to determine the significant difference between groups for quantitative or qualitative measures, respectively.

Figure legends:

Figure 1. A flowchart of study design and analytic pipeline for the genotype-first

phenome-wide longitudinal study.

A diagnostic panel of RVs (n=67) prioritized by three pipelines (P1-3) was created for

the purpose of interpreting exome sequencing results for monogenic stroke candidate

genes (*COL4A1, COL4A2, NOTCH3, HTRA1, TREX1, CTC1,* and *GLA)*. Simulated

longitudinal disease profile for a patient with RV(s) as an example to illustrate the data

extraction and PheCode mapping. The colors represent different PheCodes from the

same disease category. Cases for the specific PheCode were defined by 'Rule of Two'

from any encounter types in the EHR.

Figure 2. Circo plots with interlinks of the top 50 common diseases of which RVs

from seven CSVD risk genes having increased relative risk in early-onset

patients.

Participants with the age of onset for a specific disease after 65yrs were considered null

for the early-onset phenotype; A circo plot was created based on the top 50 PheCodes

ranked by precent relative effect (PRE) and clustered by the processes. The links

represent the significant association between two PheCodes in RV carriers calculated

by Fisher's exact test after correction for multiple testing (p < 0.001 given 50 phecodes

being tested)). Significant associations for adjacent PheCodes were labeled with spike

but not linked. Y axis represents PRE; The area of the dot was proportional to the

significant association between carriers and the corresponding disease according to

Fisher's exact test. Diseases from the circulatory system were overrepresented in early-

onset carriers in both cohorts with EUR or AFR ancestry. Disease categories with the

number of PheCodes >= 2 were plotted.

Figure 3. Kaplan-Meier estimated the cumulative probability of ischemic

cerebrovascular disease for RV carriers compared to matched noncarriers, a

gene- and race- dependent association.

A. EUR in discovery cohort; **B**. EUR in replication cohort; **C**. AFR in

discovery/replication cohort. Carriers for genes other than COL4A1/2 were too low to

show in AFR subgroups. Only patients with European (EUR) or African (AFR) ancestry

were included in this study. Ischemic cerebrovascular disease was determined by six

PheCodes. The follow-up was censored on 12/06/2021. A Lifelong (up to 85yrs) Log-

rank test was applied to comparing carriers for each gene to the shared noncarriers for

all seven genes. For post-hoc pairwise tests, p-values were present as raw. Cox

proportional-hazards regression model, adjusted for sex, index age, and five principal

components, was conducted to determine the association between collapsed RVs from

each gene or combined and the IS. Adjusted Hazard Ratios (HR) estimates and their

95% confidence intervals (Cis) for a lifetime (up to 85yrs) or early-onset (≤65yrs) risk

were present in the forest plot.

Figure 4. Kaplan-Meier estimated the cumulative probability of IS for carriers

compared to matched noncarriers, a sex-dependent analysis.

For post-hoc pairwise Log-rank tests, p-values were present as raw. The effect size

(HR) was observed to be larger in Female than Male carriers. A. NOTCH3 in the

discovery EUR cohort; B. TREX1 in the replication EUR cohort; C. COL4A1 in both

discovery and replication AFR cohort. Cox proportional-hazards regression model,

adjusted for sex, index age, and five principal components, was conducted to determine

the association between collapsed RVs from each gene and the IS. Adjusted Hazard

Ratios (HR) estimates and their 95% confidence intervals (Cis) for a lifetime (up to

85yrs) or early-onset (≤65yrs) risk were present in the forest plot.

Figure 5. PheCode Set Enrichment Analysis was conducted to determine which

disease categories were significantly enriched.

A. A graph that corresponds to a calculation of enrichment score. Each breakpoint on a

graph corresponds to a PheCode present in the disease category (e.g., Circulatory

system). The curve goes rightward when phecode $\notin$ disease category and goes upward

when $\in$ phecode sets**. B.** For example, in Discovery(EUR), the point corresponds to

PheCode ranked the 71th from the entire PheCode of common diseases of any

category, where the maximal value of the enrichment score is reached. The vertical

bars along the x-axis represent 69 PheCodes belonging to the interrogated disease

category(e.g., the circulatory system). The vertical dash line defined "leading edge

subset" as all those PheCodes (in bracket) ranked as least as high as the enriched set,

and the enriched score reached the maximum. **C.** The forest plot was created to show

the effect size of significantly enriched PheCode sets from each disease category in

Discovery(EUR), where the common diseases were ranked based on Percent Relative

Effect (PRE). The raw and adjusted p-value for multiple testing using BH procedure was

listed. **D**. Validation across cohorts or across races using the PheCode set derived from

the circulatory system as examples**.** The PheCode set enrichment analysis has two

input objects: 1) an array of pre-ranked PheCode-level statistics S (PRE) for the

PheCode $U = \{1, 2, \ldots, N\}$, shown as Rank List (y-axis); 2) a list of query PheCode

sets P which consist of 18 enriched PheCode sets from the corresponding 18 disease

categories. The goal of the analysis is to determine which of the 18 PheCode sets

enriched from one dataset also shows a non-random overrepresentation in the other

dataset. Here we only reported the result of PheCode Sets derived from the Circulatory

system (x-axis).

Table 1. Patient characteristics of RVs carriers or noncarriers in both Discovery and

Replication cohorts.

Cohort	Discovery				Replication				Prevalence of common diseases estimated from noncarriers (%)
	Carriers		NonCarriers		Carriers		NonCarriers		
Characteristic	Number of cases	cumulative incidence (‰)	Number of cases	cumulative incidence (‰)	Number of cases	cumulative incidence (‰)	Number of cases	cumulative incidence (‰)	
sample size	2738		5490		1695		3410		
Index_age	57.18(18.34)		56.99(18.35)		52.04(18.73)		52.52(19.45)		
Male(%)	1028(37.55%)		2053(37.4%)		612(36.11%)		1185(34.75%)		
American Indian Or Alaska Native	2 (0.07%)		5 (0.09%)		5 (0.29%)		17 (0.50%)		
Asian	9 (0.33%)		14 (0.26%)		1 (0.06%)		2 (0.06%)		
Native Hawaiian Or Other Pacific Islander	2 (0.07%)		3 (0.05%)		5 (0.29%)		28 (0.82%)		
Unknown(Multi-ancestry)	8 (0.29%)		16 (0.29%)		9 (0.53%)		28 (0.82%)		
White	2586 (94.45%)		5242 (95.46%)		1474(86.96%)		3036 (89.03%)		
Black Or African American	131 (4.77%)		211 (3.84%)		201 (11.79%)		299 (8.77%)		
Other and unspecified coagulation defects(286.7)	42/34*	15.34/12.42	70/44	12.75/8.01	22*/18*	12.98/10.62	25/20	7.33/5.87	1.1
Hypercoagulable state(286.8)	63***/50**	23.01/18.26	74/63	13.48/11.48	22/17	12.98/10.03	39/30	11.44/8.8	1.33
Primary hypercoagulable state(286.81)	61***/49**	22.28/17.9	74/63	13.48/11.48	22/17	12.98/10.03	38/30	11.14/8.8	1.3
Heart valve disorders(395)	213/108	77.79/39.44	453/180	82.51/32.79	89/42	52.51/24.78	198/87	58.06/25.51	7.43
Abnormal heart sounds(396)	74/50	27.03/18.26	142/84	25.87/15.3	32/26	18.88/15.34	93/55	27.27/16.13	2.59
Hypertension(401)	1419/1084	518.26/395.91	2898/2211	527.87/402.73	720/556	424.78/328.02	1465/1105	429.62/324.05	50.06
Myocardial infarction(411.2)	133/78	48.58/28.49	336/174	61.2/31.69	47/30	27.73/17.7	88/48	25.81/14.08	4.99
Coronary atherosclerosis(411.4)	448/234	163.62/85.46	954/532	173.77/96.9	169/99**	99.71/58.41	319/149	93.55/43.7	15.06
Pulmonary heart disease(415)	153/72	55.88/26.3	323/166	58.83/30.24	54/32	31.86/18.88	101/51	29.62/14.96	4.7
Cardiomyopathy(425)	80/49	29.22/17.9	156/86	28.42/15.66	51/39	30.09/23.01	88/52	25.81/15.25	3
Primary/intrinsic cardiomyopathies(425.1)	72/43	26.3/15.7	137/76	24.95/13.84	49/37**	28.91/21.83	75/44	21.99/12.9	2.71
Cardiac conduction disorders(426)	260/141	94.96/51.5	512/282	93.26/51.37	142/88**	83.78/51.92	253/125	74.19/36.66	10.29
Atrial fibrillation and flutter(427.2)	263/92	96.06/33.6	568/191	103.46/34.79	105/55	61.95/32.45	238/84	69.79/24.63	9.23
Intracranial hemorrhage(430)	33/13	12.05/4.75	69/29	12.57/5.28	16/6	9.44/3.54	24/15	7.04/4.4	1.08
Cerebrovascular disease(433)	349/176	127.47/64.28	663/315	120.77/57.38	138/76**	81.42/44.84	243/114	71.26/33.43	10.33
Occlusion and stenosis of precerebral arteries(433.1)	209/92	76.33/33.6	409/175	74.5/31.88	69/30	40.71/17.7	142/56	41.64/16.42	6.35
Occlusion of cerebral arteries with cerebral infarction(433.11)	22/11	8.04/4.02	41/21	7.47/3.83	5/3	2.95/1.77	14/6	4.11/1.76	0.56
Cerebral atherosclerosis(433.12)	83/35	30.31/12.78	165/62	30.05/11.29	24/12	14.16/7.08	52/27	15.25/7.92	2.37
Occlusion of cerebral arteries(433.2)	93/49	33.97/17.9	161/74	29.33/13.48	37/19	21.83/11.21	65/28	19.06/8.21	2.53

Cerebral artery occlusion with cerebral infarction(433.21)	93/49	33.97/17.9	161/74	29.33/13.48	36/18	21.24/10.62	63/26	18.48/7.62	2.47
Cerebral ischemia(433.3)	188/102*	68.66/37.25	358/160	65.21/29.14	62/36	36.58/21.24	124/56	36.36/16.42	5.33
Transient cerebral ischemia(433.31)	177/88*	64.65/32.14	325/136	59.2/24.77	61/35	35.99/20.65	119/54	34.9/15.84	4.92
Cerebral aneurysm(433.5)	22/14	8.04/5.11	44/34	8.01/6.19	16/11	9.44/6.49	19/13	5.57/3.81	0.67
Late effects of cerebrovascular disease(433.8)	67/30	24.47/10.96	110/51	20.04/9.29	13/7	7.67/4.13	31/15	9.09/4.4	1.64
Peripheral vascular disease unspecified(443.9)	165/83	60.26/30.31	384/169	69.95/30.78	63/37**	37.17/21.83	105/45	30.79/13.2	5.36
Deep vein thrombosis [DVT](452.2)	91/53	33.24/19.36	151/86	27.5/15.66	25/15	14.75/8.85	76/43	22.29/12.61	2.49

Figure 1. A flowchart of study design and analytic pipeline for the genotype-first phenome-wide longitudinal study.

Figure 2. Circo plots with interlinks of the top 50 common diseases of which rare variants from seven CSVD risk genes having increased relative risk in early-onset patients.

Figure 3. Kaplan-Meier estimated the cumulative probability of ischemic cerebrovascular disease for rare variant carriers comparing to matched noncarriers, a gene- and race- dependent association.

C.

Cumulative probability for 85yrs
Disease = ischemic stroke 6 PheCodes Carriers vs NonCarriers for COL4A1/2 in either discovery or replication cohorts

Strata																
Carrier-Discovery	125	125	123	123	121	114	102	87	72	56	49	38	25	11	5	4	2
Carrier-Replication	179	178	175	172	169	163	147	127	114	93	79	57	46	32	14	5	2
NonCarrier-Discovery	211	211	209	208	205	193	174	155	137	107	82	56	38	19	12	7	4
NonCarrier-Replication	299	290	284	277	272	250	226	192	166	135	111	81	49	32	17	7	4

| | 0 | 5 | 10 | 15 | 20 | 25 | 30 | 35 | 40 | 45 | 50 | 55 | 60 | 65 | 70 | 75 | 80 |

Time in years

Plotted with R survminer

Figure 4. Kaplan-Meier estimated the cumulative probability of ischemic stroke for carriers compared to matched noncarriers, a sex-dependent analysis.

C.

Cumulative probability for 85yrs
Disease = ischemic stroke 6 phecodes in both discovery and replication cohorts

Strata — HTRA1-Female — HTRA1-Male — NonCarrier-Female — NonCarrier-Male

Gene	Sex		Onset	P value	Hazard Ratio (95%CI)
HTRA1	Combined		Early	0.393	0.545(0.136-2.192)
HTRA1	Combined		Lifetime	0.489	1.28(0.636-2.575)
HTRA1	Male		Early	0.44	0.46(0.064-3.296)
HTRA1	Male		Lifetime	0.98	1.013(0.377-2.72)
HTRA1	Female		Early	0.689	0.669(0.094-4.782)
HTRA1	Female		Lifetime	0.263	1.758(0.654-4.722)

estimate(95%CI): 0.088 0.250 0.707 2.00 6.00

0.257

0.980

Cumulative Incidence — Time in years

Plotted with R survminer

Cumulative probability for 85yrs
Disease = ischemic stroke 6 phecodes in both discovery and replication cohorts

Strata	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80
HTRA1-Female	62	62	61	60	60	55	50	45	40	40	36	31	23	19	6	2	2
HTRA1-Male	55	54	53	53	52	49	49	49	47	45	39	34	26	21	11	6	4
NonCarrier-Female	5276	5268	5245	5231	5192	4995	4662	4281	3901	3561	3164	2712	2229	1661	1157	746	451
NonCarrier-Male	3001	2988	2927	2901	2866	2815	2740	2644	2527	2360	2148	1838	1532	1205	816	510	272

Plotted with R survminer

D.

Cumulative probability for 85yrs
Disease = ischemic stroke 6 phecodes in both discovery and replication cohorts

Strata — COL4A1-Female — COL4A1-Male — NonCarrier-Female — NonCarrier-Male

Gene	Sex		Onset	P value	Hazard Ratio (95%CI)
COL4A1	Combined		Early	0.07	1.907(0.948-3.838)
COL4A1	Combined		Lifetime	0.031	2.032(1.065-3.875)
COL4A1	Male		Early	0.421	1.566(0.525-4.674)
COL4A1	Male		Lifetime	0.305	1.68(0.624-4.522)
COL4A1	Female		Early	0.097	2.163(0.87-5.38)
COL4A1	Female		Lifetime	0.055	2.304(0.984-5.398)

estimate(95%CI): 0.5 1.5 2.5 3.5 4.5 5.5

0.048

0.299

Cumulative Incidence — Time in years

Strata	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80
COL4A1-Female	179	179	177	175	174	165	144	123	103	83	65	49	33	19	9	4	1
COL4A1-Male	125	124	121	120	116	112	105	91	83	66	63	46	38	24	10	5	3
NonCarrier-Female	306	303	302	297	290	266	234	198	171	130	104	74	45	26	17	6	5
NonCarrier-Male	204	198	191	188	187	177	166	149	132	112	89	63	42	25	12	8	3

Figure 5. PheCode Set Enrichment Analysis was conducted to determine which disease categories were significantly enriched.

A. Discovery (EUR)

circulatory system ("395" "395.1" "395.2" "396" "420" "425" "425.1" "426.7" "429.3" "433" "433.12" "433.2" "433.21" "433.3" "433.31" "443.1" "452" "452.2")

B.

Cut_point	Enrichment_score_max	Category	TotalNum	Num
536	0.061	infectious diseases	11	11
15	0.361	neoplasms	10	2
22	0.096	endocrine & metabolic	64	3
24	0.364	hematopoietic	19	4
54	0.267	mental disorders	29	5
49	0.212	neurological	21	3
566	0.007	sense organs	35	35
71	0.295	circulatory system	69	18
9	0.054	respiratory	40	1
564	0.012	digestive	56	56
75	0.230	genitourinary	68	16
64	0.204	pregnancy complications	13	3
545	0.047	dermatologic	43	43
0	0.000	musculoskeletal	39	28
570	0.000	musculoskeletal	39	28
571	0.000	musculoskeletal	39	28
19	0.491	congenital anomalies	6	2
538	0.059	symptoms	26	26
5	0.213	injuries & poisonings	21	1

C.

Category	Phecode ranks	NES	pval	padj
circulatory system		2.95	1.7e-11	2.8e-10
genitourinary		2.80	1.3e-09	1.1e-08
hematopoietic		1.92	2.1e-04	1.2e-03
mental disorders		1.97	6.4e-04	2.2e-03
endocrine & metabolic		1.76	1.2e-03	3.5e-03
neoplasms		1.53	6.8e-03	1.5e-02
neurological		1.68	1.0e-02	1.8e-02
congenital anomalies		1.52	1.1e-02	1.8e-02
injuries & poisonings		1.34	1.6e-02	2.5e-02
pregnancy complications		1.63	2.2e-02	3.1e-02
respiratory		1.33	3.1e-02	4.1e-02
infectious diseases		-0.89	6.4e-01	6.4e-01
symptoms		-1.06	3.8e-01	4.1e-01
sense organs		-1.28	1.3e-01	1.5e-01
dermatologic		-1.40	4.9e-02	5.9e-02
musculoskeletal		-1.61	6.3e-03	1.5e-02
digestive		-1.72	4.5e-04	1.9e-03

D.